Patients

The World Health Organization predicts neurodegenerative diseases will become the second-most prevalent cause of death within the next 20 years¹. With this sense of urgency, we are committed to expanding the treatment options for individuals with neurodegenerative disease and their caregivers through our innovative research, discovery, development, and manufacturing of novel therapeutics. Clene is uniquely positioned to chart a path that allows its technology to fully intervene in human disease in a way that no technology previously has, revolutionizing the future of neurodegenerative therapeutics.

Our Clinical Trials

Amyotrophic Lateral Sclerosis (ALS)

• HEALEY-ALS Platform: NCT04414345
• RESCUE-ALS: NCT04098406
  • EAP: NCT04081714
  • EAP: NCT05281484
• REPAIR-ALS: NCT03843710

Multiple Sclerosis (MS)

• REPAIR-MS: NCT03993171
• VISIONARY-MS: NCT03536559
• VISIONMS-LTE: NCT04626921

Parkinson’s Disease

• REPAIR-PD: NCT03815916

Covid

• Treatment of Covid-19 Symptomatic Patients: NCT04610138

References:
¹Gammon, K. Neurodegenerative disease: Brain windfall. Nature 515, 299–300 (2014).